Agenda

Displaying agenda in the event’s time zone (EDT, UTC -4)

CONFERENCE DAY 2
Wednesday, September 22, 2021
CONFERENCE DAY 2
Thursday, September 23, 2021
CONFERENCE DAY 3
Friday, September 24, 2021

Pre-Conference Masterclass: BEST PRACTICES IN CONDUCTING CI IN ONCOLOGY

Dr. Paul De Santis (PharmD), Senior Director, Molekule Consulting

Oncology is a complex and nuanced therapeutic area that requires a heightened level of awareness across clinical, regulatory, commercial, and market access functions.

Many approach CI in oncology through the same lens as other therapeutic areas, but doing so may inadvertently lead to an unawareness of the landscape. As a result, stakeholders making strategic decisions may be at risk of doing so based on inaccurate or outdated intelligence. Today’s workshop will translate key learnings from Molekule’s experience in oncology into best practices for those starting or entering into a new CI program in oncology.

In this workshop, participants will identify appropriate sources for monitoring the oncology landscape, then practice discerning a major event from an immaterial event and translating this into an actionable real-time alert that maximizes impact for all stakeholders. This will be followed by a review of the alert to help build awareness and vigilance regarding best practices in oncology.

This Workshop is facilitated by Dr. Paul De Santis (PharmD), Senior Director of Molekule Consulting, a global competitive intelligence and strategy consultancy dedicated to the life sciences and biopharmaceutical verticals. Paul has 15+ years’ experience in oncology spanning clinical and translational research through commercialization. Paul is a Subject Matter Expert in lymphoma, multiple myeloma, and cell therapy; with a passion for CAR T commercialization and maximizing patient access to CAR T.

Presented by Molekule Consulting

Welcome from the Co-Chairs and Advisory Board Plus Pandemic Push-Through for Stakeholders

Presented by Abbott Laboratories, Bayer Consumer Health, BioMarin, Boehringer Ingelheim, Eli Lilly and Company, Johnson & Johnson, and Novartis

Keynote: Using the DrugOme™ – Translating Analytics to Action

Initiated about 5 years ago, Sumitovant's Computational Research and Analytics team has continued the expansion of an analytic ecosystem developed to solve strategic pharma questions.

We call this ecosystem the DrugOme™. The DrugOme™, supports analyses for the strategic decisions of many groups in a therapeutic area agnostic way across all phases of drug development, from discovery through commercialization. We discuss the challenges involved in translating technology-driven insight into action across many groups in many companies and across all phases of drug development.

Presented by Sumitovant Biopharma

Keynote: HOW TO BUILD A SUCCESSFUL AND SUSTAINABLE CI FUNCTION

Dr. Daniel Pascheles, CEO, Molekule Consulting

Daniel will share with the audience his learnings and experiences in building and leading successfully several CI teams over a time span of more than 20 years in the industry.

Topics we will cover:
• What are the 10 “commandments” to build a successful CI team
• What is needed to make the CI team relevant and impactful for a company
• How to recruit the best CI talent into the department and retain them
The audience can expect to be able to participate actively in the “conversation” and contribute to the program

Presented by Molekule Consulting

Virtual Exhibition Hall

Luncheon Break and One-on-One Meetings

SESSION

CAR-T Cell Therapy Market

Primer plus how to cover cell therapy because of its vastness, volume of unknowns and also evolving needs of the company

Presented by Atara Biotherapeutics

BREAKOUT ROUNDTABLE

CI: Staying Relevant and Delivering Impact

Presented by Janssen

SESSION ONE
Enriching Pharma CI With Expertly Curated Content and Digital Tools: An ASCO 2021 Case Study

• Data overwhelm challenge pharma teams are facing

• Information management from public domain: sifting through the ‘noise’
• Using the hybrid of technology and human touch to create successful outcomes
• Case study: ASCO2021

Presented by LARVOL

SESSION TWO
Leveraging AI to Evaluate the Commercial Impact of Competitive Developments

Presented by Sentieo

Virtual Exhibition Hall

SESSION ONE

Gaining Competitive Edge through Pipeline Optimization

We will focus on how to remain competitive in the pharma industry today, by showcasing examples of two ‘hot’ novel therapies and highlighting the importance of innovation and maintaining a diversified early pipeline. We will also share the perspectives of pioneers we have interviewed in this field and discuss how CI can help map the white space.

Presented by Cambridge Healthcare Research

SESSION TWO

The Missing Link to Your Research: How Leading CI Professionals Leverage AI to Streamline Workflows

CI professionals in Pharma are regularly consuming and analyzing large volumes of patient research and diagnostic data — but it’s growing more and more difficult to conquer information overload and to do it before anyone else.

In one of the most rapidly-changing industries in the world, how do you ensure you’re staying on top of new developments while also surfacing relevant insights quickly to your leadership team?

Join experts, Diana Gowe, Director, Strategy, Analytics & Business Transformation at Johnson & Johnson, and Craig Farrell, Director of GTM Strategy, Life Sciences at AlphaSense, as they share the success secrets behind leading CI teams and why AI is crucial to being first in the market.

In this session, you’ll walk away with:

Game-changing best practices for competitive monitoring so you can deliver quarterly reports faster and more efficiently
Tactics used by Johnson & Johnson’s leading CI team for tracking key competitors (alerts, thematic and KPI extraction, semantic search, and access to broker research)
Real-life examples of how to make the most of your research platform’s customer service team so you never miss a deadline again

Presented by Alphasense and Johnson & Johnson

Concurrent Panels

PANEL ONE
Licensing, Partnering and Strategic Initiatives

Presented by ADC Therapeutics, Amicus Therapeutics, Roche Diagnostics, and Spectrum Pharmaceuticals

PANEL TWO
Career Conversation with Insights Experts: What’s Next After CI and How to Get There

Presented by Abbott, B. Riley Securities, Merck, Molekule Consulting, and Regeneron

One-On-One Meetings

PRE-CONFERENCE MASTERCLASS: Developing a Competitive Activity Framework to Enhance Organizational Competitiveness

Dr. Harshal Kubavat, Head of Strategic Consulting, INOVIS Life Sciences

This workshop session will give participants first-hand insights from a combined 30+ years of experience in delivering strategic and tactical workshop-style solutions, using an optimal blend of established CI frameworks alongside INOVIS’ in-house proprietary methodologies.

Key to this session will be addressing business needs across the lifecycle, whereby participants will:
• Develop an in-depth understanding of how a diverse range of facilitated activities (Rapid Immersion, Threat Assessment and Competitor Simulations) can help deliver strategic and competitive insights within an organization
• Appreciate the importance of leveraging the outcomes of workshops to inform and direct decision making
• Receive hands-on opportunities to apply learnings to a pharma case-study in a learning environment

Using business case studies, real-life experiences and validated theory, the INOVIS team will equip you with a number of go-to techniques that can be rapidly integrated into ongoing CI Practice, whether you’re a seasoned CI professional veteran, or newer to the field.

Presented by INOVIS

Welcome and Re-Cap of Day One

Presented by Bayer and Johnson & Johnson

Keynote: Accelerated COVID-19 Vaccine Development – A Testament to Scientific Advancement, Regulatory, and Institutional Collaborations

Since the emergence of COVID‐19, caused by the SARS‐CoV‐2 virus first identified at the end of 2019, there has been an explosion of vaccine development.

Due to the rapid spread of COVID-19 and lack of reliable treatment options at the outset of the pandemic, vaccinations became a viable option to fight the pandemic.

In this presentation, we will review the significant hurdles that the pharmaceutical industry overcame to successfully develop and distribute the vaccines specifically in the US and EU, including:

• scientific advancements, including use of mRNA-based technology in vaccines allowed rapid manufacturing
• regulatory streamlining allowing initiation of multiple clinical trial phases and emergency authorizations to shorten the developmental timeline
• institutional collaborations and funding initiatives along with unparalleled transparency
• remaining challenges as the pandemic continues and lessons learned for the first wave of vaccine development

Presented by Lifescience Dynamics

Keynote: Late Life Cycle Management (LLCM): The Strategic Value of Generic & Biosimilar CI In Life Sciences

Dr. Baljit Singh, Managing Director and Partner, INOVIS, Pharmaceuticals and Life Sciences Division (formerly Director, Integrated Insights, Novartis)

This session will provide insights and highlight best practices to enable LLCM value and asset maximization by leveraging a number of tools unique to CI professionals.

Specifically this presentation will enable you to:
• Advance your understanding of core Gx/biosimilar market dynamics and corresponding CI solutions
• Set up a best-in-industry Gx/biosimilar regulatory intelligence (RI) and CI tracking program
• Understand Gx / biosimilar product development and entry strategies

Presented by INOVIS

Virtual Exhibition Hall

Luncheon Break and One-on-One Meetings

SESSION ONE

Life Cycle Situations and Patents

Presented by EMD Sereno


SESSION TWO

Breakout Roundtable: CI in the Post Covid world from a Field Perspective

Presented by Amneal Pharmaceuticals

SESSION ONE
Leveraging Technology and AI to Achieve Integrated Insights

o Technology and AI are increasingly disrupting the Competitive Intelligence space by enabling integration of disparate data – primary and secondary, structured and unstructured, qualitative and quantitative – and providing holistic, integrated and actionable insights.

o Technology is also enabling democratization of data and insights through self-service and collaboration platforms, thus enabling CI teams to provide more impact.

Presented by DataZymes

SESSION TWO
State-of-the-art Competitive Intelligence Part 2

Tired of wrestling insights out of your data? Want to get the most out of your clinical trial data?

Please join us as we walk you through the steps ahead to integrate additional important data into your clinical trial landscape and bring untapped value to your forecasting, BD and Portfolio partners.

Presented by Ozmosi

“Ask the Experts” Interactive Breakout Groups

Explore and capture the power of participants’ insights and experiences in a fun and informal environment.
BREAKOUT 1
BD Assessments - Best Practices

Presented by Shionogi

BREAKOUT 2
CI for Rare Diseases and Gene Therapy

Presented by REGENXBIO

Virtual Exhibition Hall

Evolving CI and Data Management with Artificial Intelligence

Competitive intelligence teams have greater access to data than ever before. However, a reliance on traditional, manual data collection and synthesis processes allows critical information and insights to remain hidden.

Applying artificial intelligence to more efficiently gather, organize, and synthesize key data allows teams to draw out these key insights even within rapidly changing environments.

This presentation will explore:
● How a healthcare specific, AI-based knowledge graph facilitates better data management and analysis
● How the application of AI can reduce costs and allow your team to focus on tasks requiring human-intelligence and higher-order thinking
● How AI can provide your team with a more integrated, comprehensive view of your market by bringing together all key data sources (clinical trials, conferences, social media, earnings call reports, press releases, etc.)

Presented by Ferma.AI

Concurrent Panels

PANEL ONE
Post-Pandemic Trends

Presented by Abbott, Amneal Pharmaceuticals, Sanofi, and Verona Pharma

PANEL TWO
Insights into New Product Planning and Decision Making

Presented by AbbVie, AstraZeneca, Novartis, and Taiho Oncology

One-On-One Meetings

Welcome and Re-Cap of Day Two

Presented by Bayer and Johnson & Johnson

Keynote: CI and Execution: Leading High Growth Pharma Brands

“A mediocre strategy well executed is better than a great strategy poorly executed”

Launching a new product is exciting and intense, but transitioning a product from launch to growth requires endurance and deliberation. Furthermore, scaling requires leaders who understand the role of competitive intelligence and how to manage the increased organizational and business complexity of growth.

Having supported numerous blockbuster brands, we have identified three frameworks to help brand leaders achieve high growth. The frameworks are:
• Leading high growth
• Competitive Prioritization Assessment
• Competitive readiness

In this talk, we will introduce the three frameworks. Additionally, we will share how the CI professional can have a greater impact on high-growth brands by shifting focus from strategy to execution.

Presentation attendees will receive a copy of the article “Leading High Growth Ventures” from Harvard Business Publishing. We look forward to seeing you there!

Presented by Atacana Group

Virtual Exhibition Hall

Luncheon Break and One-on-One Meetings

SESSION ONE
Driving Growth through Licensing and Acquisitions

Presented by Harpoon Therapeutics

SESSION TWO
How to Use Competitive Intelligence to Influence Decisions and Drive Impact

Presented by Ionis Pharmaceuticals

SESSION ONE
Leveraging Scenario Planning to Drive Competitor and Market Monitoring Programs

Scenario Planning session are most often used to identify strategy options and set direction. An additional output from the scenario planning session can be indicator paths.

These paths present the changes that must occur for an event to happen, which can then drive competitor and market monitoring. The session will explore how to build an indicator pathway, identify key events along the pathway, and determine specific responses to events. Making the most of the scenario planning results and the indicator pathways also includes building a monitoring system to alert when an indicator event is about to happen and a response for when that event happens. The session will cover processes used to identify what indicators should be monitored, how to monitor, the importance of adjustability within the monitoring program, and how to prepare fast response for when the event occurs

Presented by Fletcher/CSI

SESSION TWO
Observations on the Evolution of the Competitive Intelligence Function

Presented by Deallus

Virtual Exhibition Hall

Predicting the Future of Neurology in the Post-ADUHELM World

Presented by Merck and Vyuhgenics

Advisory Board Re-Cap and Closing

Presented by Abbott Laboratories, Bayer Consumer Health, BioMarin, Boehringer Ingelheim, Eli Lilly and Company, Johnson & Johnson, and Novartis

One-On-One Meetings

“COVID-conscious” Guidelines Distributed in Detail On-site but Includes:

• Use of masks required: Please bring your own if preferred, but masks and hand sanitizer will also be provided.
• Greetings should be socially distanced: no handshakes, hugs, or kisses, etc.
• Meeting space will accommodate more spacing between attendees.
• The hotel experience will be entirely revamped with specific cleaning protocols.

error: Content is protected !!